Clinical trial
S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma
NCT00041132 · SWOG Cancer Research Network, Other · Completed
Key facts
| NCT number | NCT00041132 |
|---|---|
| Title | S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma |
| Official title | Pilot Trial of Hyper-CVAD and Methotrexate/ARA C Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma |
| Lead sponsor | SWOG Cancer Research Network, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Drug |
| Interventions | filgrastim, rituximab, cyclophosphamide, cytarabine, dexamethasone, doxorubicin, leucovorin, methotrexate, vincristine |
| Enrollment | 56 |
| Start date | Sep 1, 2002 |
| Primary completion | Nov 1, 2007 |
| Completion | Jun 1, 2011 |
| First posted | Jan 27, 2003 |
| Last update posted | Nov 1, 2012 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: